Ice Miller frequently advises and guides emerging and high growth companies on matters such as entity formation, capitalization, capital raising, alternative financing, intellectual property rights, tax matters and many other legal issues that are critical to the success of any emerging company.
Headquartered at the Indiana University Emerging Technologies Center in Indianapolis, Ind., ImmuneWorks, Inc. is a biotechnology company developing immune tolerance treatments for patients with serious lung diseases. ImmuneWorks was formed in 2006 with a vision of developing a portfolio of intellectual property into drugs approved by the U.S. Food and Drug Administration for treatment of various lung diseases. ImmuneWorks recently entered into a development agreement with Lung Rx, LLC, a wholly-owned subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), for development of its lead compound, IW001, for treatment of Idiopathic Pulmonary Fibrosis (IPF) and Primary Graft Dysfunction in patients receiving a lung transplant, and is currently conducting a Phase I clinical trial in patients with IPF.
From ImmuneWorks' inception, Ice Miller has been privileged to serve as general corporate counsel. Ice Miller has provided advice and guidance on important milestones for ImmuneWorks such as a license agreement for intellectual property from Indiana University Research and Technology Corporation, financing from private investors in a convertible note offering and related securities laws, clinical trial agreements, and most recently, its development agreement and merger agreement with Lung Rx, LLC.